170 related articles for article (PubMed ID: 7472782)
61. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
62. Cutaneous leiomyomas and leiomyosarcomas: an immunohistochemical study with p53.
Fernandez-Flores A
Rom J Morphol Embryol; 2010; 51(2):295-8. PubMed ID: 20495746
[TBL] [Abstract][Full Text] [Related]
63. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry.
Schneider J; Rubio MP; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
Eur J Cancer; 1994; 30A(4):504-8. PubMed ID: 8018409
[TBL] [Abstract][Full Text] [Related]
64. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas.
Dix B; Robbins P; Carrello S; House A; Iacopetta B
Br J Cancer; 1994 Oct; 70(4):585-90. PubMed ID: 7917901
[TBL] [Abstract][Full Text] [Related]
65. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
66. A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing.
Chakravarty G; Redkar A; Mittra I
Br J Cancer; 1996 Oct; 74(8):1181-7. PubMed ID: 8883402
[TBL] [Abstract][Full Text] [Related]
67. Uterine leiomyosarcomas and benign smooth muscle tumors: usefulness of nuclear DNA patterns studied by flow cytometry.
Tsushima K; Stanhope CR; Gaffey TA; Lieber MM
Mayo Clin Proc; 1988 Mar; 63(3):248-55. PubMed ID: 3343869
[TBL] [Abstract][Full Text] [Related]
68. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma.
Mineta H; Borg A; Dictor M; Wahlberg P; Akervall J; Wennerberg J
Br J Cancer; 1998 Oct; 78(8):1084-90. PubMed ID: 9792155
[TBL] [Abstract][Full Text] [Related]
69. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
[TBL] [Abstract][Full Text] [Related]
70. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus.
Wang L; Felix JC; Lee JL; Tan PY; Tourgeman DE; O'Meara AT; Amezcua CA
Gynecol Oncol; 2003 Aug; 90(2):402-6. PubMed ID: 12893208
[TBL] [Abstract][Full Text] [Related]
71. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status.
Niwa K; Murase T; Morishita S; Hashimoto M; Itoh N; Tamaya T
Cancer Detect Prev; 1999; 23(2):147-54. PubMed ID: 10101596
[TBL] [Abstract][Full Text] [Related]
72. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
Esposito NN; Hunt JL; Bakker A; Jones MW
Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
[TBL] [Abstract][Full Text] [Related]
73. Proliferation, ploidy and prognosis in uterine smooth muscle tumours.
Jeffers MD; Oakes SJ; Richmond JA; Macaulay EM
Histopathology; 1996 Sep; 29(3):217-23. PubMed ID: 8884349
[TBL] [Abstract][Full Text] [Related]
74. Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas.
Zhai YL; Kobayashi Y; Mori A; Orii A; Nikaido T; Konishi I; Fujii S
Int J Gynecol Pathol; 1999 Jan; 18(1):20-8. PubMed ID: 9891238
[TBL] [Abstract][Full Text] [Related]
75. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
Cornejo K; Shi M; Jiang Z
Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
[TBL] [Abstract][Full Text] [Related]
76. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas.
Lee CH; Roh JW; Choi JS; Kang S; Park IA; Chung HH; Jeon YT; Kim JW; Park NH; Kang SB; Song YS
Int J Gynecol Cancer; 2011 May; 21(4):668-72. PubMed ID: 21412163
[TBL] [Abstract][Full Text] [Related]
77. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors.
Würl P; Taubert H; Bache M; Kroll J; Meye A; Berger D; Siermann A; Holzhausen HJ; Hinze R; Schmidt H; Rath FW
Int J Cancer; 1996 Aug; 69(4):317-23. PubMed ID: 8797875
[TBL] [Abstract][Full Text] [Related]
78. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.
Kämpjärvi K; Mäkinen N; Kilpivaara O; Arola J; Heinonen HR; Böhm J; Abdel-Wahab O; Lehtonen HJ; Pelttari LM; Mehine M; Schrewe H; Nevanlinna H; Levine RL; Hokland P; Böhling T; Mecklin JP; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2012 Nov; 107(10):1761-5. PubMed ID: 23132392
[TBL] [Abstract][Full Text] [Related]
79. Recent developments in uterine mesenchymal neoplasms.
Chiang S; Oliva E
Histopathology; 2013 Jan; 62(1):124-37. PubMed ID: 23240674
[TBL] [Abstract][Full Text] [Related]
80. Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas.
Chinyengetere F; Sekula DJ; Lu Y; Giustini AJ; Sanglikar A; Kawakami M; Ma T; Burkett SS; Eisenberg BL; Wells WA; Hoopes PJ; Demicco EG; Lazar AJ; Torres KE; Memoli V; Freemantle SJ; Dmitrovsky E
BMC Cancer; 2015 Nov; 15():886. PubMed ID: 26555296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
